Moberg Pharma enters into collaboration with Allderma for launch in Scandinavia
Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden, Norway and Denmark. Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox®, Moberg Pharma’s first-generation nail fungus product.
In the collaboration, Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delivery of the product. The agreement also includes co-financing of marketing activities and market-based financial terms.
The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. The agreed terms allow for an early launch in Moberg Pharma’s home market closely after market approval, expected in 2023.
“Rapidly after launch, Nalox® became the market leader in the Nordics and grew the market by 400%. It is very valuable for us to repeat this successful cooperation for the launch of MOB-015, a drug with much greater potential. There is also a great advantage to be directly involved in an early launch prior to additional launches with our partners," says Anna Ljung, CEO Moberg Pharma AB.
“We look forward to the launch of MOB-015, the first topical drug with equal antifungal efficacy as oral treatment, without the risk for severe side effects. The goal is the same as last time: to reach a market-leading position in Scandinavia," says Mimmi Frölén, CEO of Allderma AB.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: email@example.com
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on November 8th, 2021.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
About Allderma, www.allderma.se
Allderma AB is a Swedish pharmaceutical company which sells and markets OTC drugs and personal care products in the Scandinavian market. Its product range spans a number of treatment areas with a focus on skincare. Allderma has been owned since 2020 by 3iM Invest AB and is included in its Consumer Healthcare investment area.